SELECTED FINANCIAL STATEMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2018

Selected Financial Statement Information [Abstract]

Schedule of Accounts Receivable [Table Text Block]

Accounts Receivable

(in thousands)	April 30, 2018			October 31, 2017
Accounts receivable		$241,665			$225,462
Less: Allowance for doubtful accounts	(3,432		)	(3,006		)
Accounts receivable, net		$238,233			$222,456

Schedule of Costs in Excess of Billings and Billings in Excess of Costs [Table Text Block]

Costs and Estimated Earnings on Uncompleted Percentage-of-Completion Contracts

(in thousands)	April 30, 2018			October 31, 2017
Costs incurred on uncompleted contracts		$36,965			$29,491
Estimated earnings	20,980			19,902
	57,945			49,393
Less: Billings to date	(44,621		)	(41,262		)
		$13,324			$8,131
Included in the accompanying Condensed Consolidated Balance Sheets under the following captions:
Accounts receivable, net (costs and estimated earnings in excess of billings)		$15,238			$9,377
Accrued expenses and other current liabilities (billings in excess of costs and estimated earnings)	(1,914		)	(1,246		)
		$13,324			$8,131

Schedule of Inventories [Table Text Block]

Inventories

(in thousands)	April 30, 2018			October 31, 2017
Finished products		$185,987			$173,559
Work in process	45,077			39,986
Materials, parts, assemblies and supplies	149,840			128,031
Contracts in process	2,037			2,415
Less: Billings to date	(272		)	(363		)
Inventories, net of valuation reserves		$382,669			$343,628

Schedule of Property, Plant and Equipment [Table Text Block]

Property, Plant and Equipment

(in thousands)	April 30, 2018			October 31, 2017
Land		$5,887			$5,435
Buildings and improvements	94,262			91,916
Machinery, equipment and tooling	218,644			191,298
Construction in progress	4,775			5,553
	323,568			294,202
Less: Accumulated depreciation and amortization	(175,454		)	(164,319		)
Property, plant and equipment, net		$148,114			$129,883

Schedule of Research and Development Expenses [Table Text Block]

The amount of new product research and development ("R&D") expenses included in cost of sales for the six and three months ended April 30, 2018 and 2017 is as follows (in thousands):

	Six months ended April 30,				Three months ended April 30,
	2018		2017		2018		2017
R&D expenses		$26,660		$22,469		$13,953		$11,223

Schedule of Redeemable Noncontrolling Interests [Table Text Block]

Management's estimate of the aggregate Redemption Amount of all Put Rights that the Company could be required to pay is as follows (in thousands):

	April 30, 2018		October 31, 2017
Redeemable at fair value		$85,039		$82,128
Redeemable based on a multiple of future earnings	48,995		48,995
Redeemable noncontrolling interests		$134,034		$131,123

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Changes in the components of accumulated other comprehensive loss for the six months ended April 30, 2018 are as follows (in thousands):

	Foreign Currency Translation			Pension Benefit Obligation			Accumulated Other Comprehensive Loss
Balances as of October 31, 2017		($9,533	)		($1,023	)		($10,556	)
Unrealized gain	8,813			221			9,034
Amortization of unrealized loss	—			6			6
Balances as of April 30, 2018		($720	)		($796	)		($1,516	)